Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia

Hargarter, L.; Lahaye, Marjolein; Chérubin, P.; Lambert, Martin; Swarz, Marnina; Joldygulov, G.; Vischia, Flavio; Chomskaya, Veronica; Bozikas, Vasilis P.; Tsapakis, Eva-Maria; Schreiner, A.

doi:10.1080/15622975.2017.1315176

Cited by 2 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant improvements were observed in psychotic symptoms ( P <0.0001) and PSP scores ( P <0.0001), and the treatment was well tolerated. 47 …”

Section: Observational Studies and Uncontrolled Pragmatic Trials Withmentioning

confidence: 99%

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

Emsley¹,

Kilian²

2018

NDT

View full text Add to dashboard Cite

The course of schizophrenia is characterized by multiple relapses, incomplete remission of symptoms, enduring cognitive deficits, and social and occupational functional impairments. Nonadherence to antipsychotic medication is a major determinant of this poor outcome. Long-acting injectable antipsychotics were developed specifically to address the nonadherence problem and are increasingly considered as an early treatment option, in an attempt to prevent accruing morbidity. This review focuses on paliperidone palmitate, the long-acting injectable (LAI) formulation of paliperidone. After considering the pharmacology of paliperidone palmitate, we review the randomized controlled trials, as well as pertinent observational, pragmatic studies for paliperidone once-monthly injections in schizophrenia. Finally, we review the recently introduced 3-monthly formulation of paliperidone palmitate. Taken together, the studies indicate that paliperidone palmitate (PP) has good efficacy compared with placebo and comparable with other antipsychotics including risperidone. The tolerability profile of PP is similar to that of risperidone, with the most important side effects being prolactin elevation, weight gain, and extrapyramidal symptoms. Advantages of PP include the extensive research database and clinical experience with paliperidone and its parent compound risperidone, the availability of different LAI formulations (once-monthly, 3-monthly, and perhaps even longer acting formulations in future), and the novel dose initiation procedure that provides rapid onset of action without the need for oral antipsychotic supplementation.

show abstract

“…Significant improvements were observed in psychotic symptoms ( P <0.0001) and PSP scores ( P <0.0001), and the treatment was well tolerated. 47 …”

Section: Observational Studies and Uncontrolled Pragmatic Trials Withmentioning

confidence: 99%

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

Emsley¹,

Kilian²

2018

NDT

View full text Add to dashboard Cite

show abstract

“…It is generally accepted nowadays that an increase in the number and duration of hospitalization events is usually associated with non-adherence to therapy and psychotic symptoms resistance to therapy with oral antipsychotics [32]. Furthermore, several studies have shown that, despite their side effects, paliperidone palmitate and olanzapine pamoate therapies show similar costefficiency characteristics [33][34][35].…”

Section: Figurementioning

confidence: 99%

Study on Tolerability and Efficacy of Paliperidone Palmitate, Olanzapine Pamoate and Risperidone Long Acting Injection in a Romanian Sample of Patients With Schizophrenia

Enatescu¹

2020

FARMACIA

View full text Add to dashboard Cite

Due to its debilitating character and the propensity to chronicity, schizophrenia is one of the most important psychotic disorder of modern times. Recent studies have emphasized the superiority of depot long-acting antipsychotics (LAIs) versus oral antipsychotics in terms of remission maintenance and the prevention of relapses and (re)hospitalization events. Here we designed a mirror-image study meant to analyse the efficacy of one-year long LAI therapy for 21 patients admitted to the "Eduard Pamfil" Psychiatry Clinic Timisoara for which a previous one-year long oral antipsychotic therapy didn't provide satisfactory results. To further strengthen our analysis, we have also compared the mirror-image data set with the results of a parallel analysis of a control group of 11 patients under therapy with the same oral antipsychotics for an equivalent period (two years) of time. Both analyses have shown a significant reduction of re-hospitalization accompanied by a substantial alteration of PANSS scores dynamics in the group of patients treated with LAIs, thus proving the overall superiority of LAIs in comparison with oral antipsychotics. Last but not least, we critically discuss two rather sensitive issues in schizophreni a therapy, the high level of polypharmacy and a hidden bias of clinical psychiatrists in selecting the patients suitable for therapeutic switch from oral to depot antipsychotics. Rezumat Studiile existente au evidențiat superioritatea antipsohticelor depot (LAI) față de antipsihoticele orale, în menținerea remisiunii, prevenirea recăderilor și implicit a respitalizărilor. Am efectuat o cercetare de tip mirror-image study, care a inclus 21 de pacienți ce au fost inițiați în cadrul Clinicii de Psihiatrie "Eduard Pamfil" Timișoara pe unul din antipsihotice atipice depot disponibile în țara noastră, după eșecul tratamentului cu antipsihotice orale ce a avut o durată de minim un an de zile anterior acestei inițieri. Pentru a reconfirma eficacitatea măsurată prin numărul mediu de spitalizări a fost făcută și o a doua analiză comparativă folosind datele unui grup de control format din 11 pacienți ce au beneficiat de tratament cu un același antipsihotic oral pe o durată de minim 2 ani de zile. Atât analiza de tip mirror-image efectuată în cadrul grupului cu antipsihotice depot, cât și compararea acestuia cu grupul de control a evidențiat o reducere semnificativă a numărului de spitalizări sub tratamentul cu antipsihotice depot. Mai mult, evoluția mediilor scorurilor în scala PANSS și a celor din subscalele acesteia a fost una semnificativă în favoarea eficacității tratamentului cu antipsihotice depot. Prezența evenimentelor adverse legate de tratament este o realitate clinică și apare la o majoritate covârșitoare a pacienților tratați cu antipsihotice LAI. Nivelul crescut de polipragmazie în tratamentul schizofreniei în ambele grupuri luate în considerare, precum și existența unui anumit subiectivism al practicienilor în alegerea cazurilor pentru tratamentul cu antipsihotice depot, au constituit alte două rez...

show abstract

Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia

Cited by 2 publications

References 39 publications

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

Study on Tolerability and Efficacy of Paliperidone Palmitate, Olanzapine Pamoate and Risperidone Long Acting Injection in a Romanian Sample of Patients With Schizophrenia

Contact Info

Product

Resources

About